US5766619A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical dosage form for ocular administration and preparation process
Assignee: Carl Zeiss Meditec SAS
•
Filing: 1993-05-04
•
Granted: 1998-06-16
•
Expires: 2013-05-04
Abstract
Abstract PCT No. PCT/FR93/00433 Sec. 371 Date Nov. 4, 1994 Sec. 102(e) Date Nov. 4, 1994 PCT Filed May 4, 1993 PCT Pub. No. WO93/21901 PCT Pub. Date Nov. 11, 1993An insoluble pharmaceutical dosage form for ocular administration including a matrix including at least one polymer and at least one active ingredient and a first layer of glycerides distributed at least over a surface of the matrix. The dosage form is an insoluble solid tablet.
Inventors
- 👤 Jean-Marc Aiache
- 👤 Gilbert Serpin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 19:33
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/0012; A61K9/0048; A61K9/0051; A61K9/28; A61P; A61P31/00; A61P31/04
Claims Analysis
Total Claims: 43
Claim 1
Independent Claim
67 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer including at least one member selected from the group consisting of polyethylene, acrylic polymers, polyvinyl chloride, hydroxpropylmethylcellulose, polyvinylalcohol, and polymeric methacrylates and at least one active ingredient; and a first layer of glycerides distributed at least over the surface of the matrix; wherein the dosage form is an insoluble solid tablet.
Claim 2
Dependent Claim
67 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer including at least one member selected from the group consisting of polyethylene, acrylic polymers, polyvinyl chloride, hydroxpropylmethylcellulose, polyvinylalcohol, and polymeric methacrylates and at least one active ingredient; and a first layer of glycerides distributed at least over the surface of the matrix; wherein the dosage form is an insoluble solid tablet.
Claim 3
Dependent Claim
19 words
An insoluble pharmaceutical dosage form according to claim 1, further comprising a second layer forming a semipermeable outer membrane.
Claim 4
Dependent Claim
51 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient; and a first layer of glycerides distributed at least over the surface of the matrix and present within the matrix; wherein the dosage form is an insoluble solid tablet.
Claim 5
Dependent Claim
51 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient; and a first layer of glycerides distributed at least over the surface of the matrix and present within the matrix; wherein the dosage form is an insoluble solid tablet.
Claim 6
Dependent Claim
70 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient; a first layer of glycerides distributed at least over the surface of the matrix; and a second layer forming a semipermeable outer membrane formed from a substituted thermoplastic cellulose compound selected from the groups consisting of ethers and esters; wherein the dosage form is an insoluble solid tablet.
Claim 7
Dependent Claim
70 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient; a first layer of glycerides distributed at least over the surface of the matrix; and a second layer forming a semipermeable outer membrane formed from a substituted thermoplastic cellulose compound selected from the groups consisting of ethers and esters; wherein the dosage form is an insoluble solid tablet.
Claim 8
Dependent Claim
82 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient; and a first layer of glycerides distributed at least over the surface of the matrix; wherein the dosage form is an insoluble solid tablet and wherein the dosage form includes by total weight of said dosage form between 1 and 60% of said active ingredient, between 25 and 70% of said polymer, and between 8 and 40% of said glycerides.
Claim 9
Dependent Claim
82 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient; and a first layer of glycerides distributed at least over the surface of the matrix; wherein the dosage form is an insoluble solid tablet and wherein the dosage form includes by total weight of said dosage form between 1 and 60% of said active ingredient, between 25 and 70% of said polymer, and between 8 and 40% of said glycerides.
Claim 10
Dependent Claim
18 words
An insoluble pharmaceutical dosage form according to claim 1, wherein said glycerides are natural or semisynthetic solid glycerides.
Claim 11
Dependent Claim
77 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient, said polymer including at least one member selected from the group consisting of polyethylene, acrylic polymers, polyvinyl chloride, hydroxypropylmethylcellulose, polyvinylalcohol, and polymeric methacrylates; a first layer of glycerides distributed at least over the surface of the matrix; and a second layer forming a semipermeable outer membrane; wherein the dosage form is an insoluble solid tablet.
Claim 12
Dependent Claim
77 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient, said polymer including at least one member selected from the group consisting of polyethylene, acrylic polymers, polyvinyl chloride, hydroxypropylmethylcellulose, polyvinylalcohol, and polymeric methacrylates; a first layer of glycerides distributed at least over the surface of the matrix; and a second layer forming a semipermeable outer membrane; wherein the dosage form is an insoluble solid tablet.
Claim 13
Dependent Claim
20 words
An insoluble pharmaceutical dosage form according to claim 2, wherein said semipermeable membrane is formed from a thermoplastic cellulose compound.
Claim 14
Dependent Claim
28 words
An insoluble pharmaceutical dosage form according to claim 2, wherein said semipermeable membrane is formed from a compound selected form the group consisting of ethylcellulose and cellulose acetate.
Claim 15
Dependent Claim
28 words
An insoluble pharmaceutical dosage form according to claim 1, wherein said active ingredient includes at least one member selected from the group consisting of mydriatics, antibiotics and anti-inflammatories.
Claim 16
Dependent Claim
40 words
An insoluble pharmaceutical dosage form according to claim 1, including by total weight of said dosage form between 1 and 60% of said active ingredient, between 25 and 70% of said polymer, and between 8 and 40% of said glycerides.
Claim 17
Dependent Claim
31 words
An insoluble pharmaceutical dosage form according to claim 1, wherein said dosage form is between approximately 2.5 and 4 mm in length and between approximately 1 and 3 mm in diameter.
Claim 18
Dependent Claim
70 words
A process for preparing an insoluble pharmaceutical dosage form, said process comprising the steps of: a) mixing at least one active ingredient with at least one polymer, said active ingredient and said polymer comprising a matrix; b) adding a first layer of glycerides over at least a surface of said matrix; c) mixing said glycerides and said matrix to form a mixture; and d) forming said mixture into a tablet.
Claim 19
Dependent Claim
70 words
A process for preparing an insoluble pharmaceutical dosage form, said process comprising the steps of: a) mixing at least one active ingredient with at least one polymer, said active ingredient and said polymer comprising a matrix; b) adding a first layer of glycerides over at least a surface of said matrix; c) mixing said glycerides and said matrix to form a mixture; and d) forming said mixture into a tablet.
Claim 20
Dependent Claim
30 words
A process for preparing an insoluble pharmaceutical dosage form according to claim 13, further comprising the steps of: wetting said mixture; incorporating adjuvants into said mixture; and granulating said mixture.
Claim 21
Dependent Claim
30 words
A process for preparing an insoluble pharmaceutical dosage form according to claim 13, further comprising the step of: coating the tablet with a second layer forming a semipermeable outer membrane.
Claim 22
Dependent Claim
29 words
A process for preparing an insoluble pharmaceutical dosage form according to claim 15 wherein said second layer is formed from a thermoplastic cellulose compound dissolved in an organic solvent.
Claim 23
Dependent Claim
46 words
A process for preparing an insoluble pharmaceutical dosage form according to claim 15, wherein said coating is performed by dipping the tablets in a solution of ethylcellulose in an organic solvent and said process further comprises the step of drying said coated tablets in an oven.
Claim 24
Dependent Claim
21 words
An insoluble pharmaceutical dosage form according to claim 1, wherein said first layer of glycerides is also present within the matrix.
Claim 25
Dependent Claim
20 words
A process according to claim 13, further comprising the step of: adding said first layer of glycerides within said matrix.
Claim 26
Dependent Claim
30 words
An insoluble pharmaceutical dosage form according to claim 2, wherein said semipermeable membrane is formed from a substituted thermoplastic cellulose compound selected from the groups consisting of ethers and esters.
Claim 27
Dependent Claim
34 words
A process for preparing an insoluble pharmaceutical dosage form according to claim 15, wherein said second layer is formed from a substituted thermoplastic cellulose compound selected from the groups consisting of ethers and esters.
Claim 28
Dependent Claim
32 words
A process for preparing an insoluble pharmaceutical dosage form according to claim 15, wherein said second layer is formed from a compound selected from the group consisting of ethylcellulose and cellulose acetate.
Claim 29
Dependent Claim
14 words
An insoluble pharmaceutical dosage form according to claim 1, wherein said glycerides are triglycerides.
Claim 30
Dependent Claim
51 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient; and a first layer of natural or semisynthetic solid glyceryl behenate distributed at least over a surface of the matrix; wherein the dosage form is an insoluble solid tablet.
Claim 31
Dependent Claim
51 words
An insoluble pharmaceutical dosage form for ocular administration, comprising: a matrix including at least one polymer and at least one active ingredient; and a first layer of natural or semisynthetic solid glyceryl behenate distributed at least over a surface of the matrix; wherein the dosage form is an insoluble solid tablet.
Claim 32
Dependent Claim
29 words
The insoluble pharmaceutical dosage form according to claim 24, further comprising: a second layer of a semipermeable membrane on at least one of said first layer and said matrix.
Claim 33
Dependent Claim
20 words
The insoluble pharmaceutical dosage form according to claim 24, wherein said semipermeable membrane is formed from a thermoplastic cellulose compound.
Claim 34
Dependent Claim
16 words
The insoluble pharmaceutical dosage form according to claim 7, wherein said dosage form is a tablet.
Claim 35
Dependent Claim
18 words
The insoluble pharmaceutical dosage form according to claim 7, wherein said glycerides are natural or semisynthetic solid glycerides.
Claim 36
Dependent Claim
20 words
The insoluble pharmaceutical dosage form according to claim 7, wherein said semipermeable membrane is formed from a thermoplastic cellulose compound.
Claim 37
Dependent Claim
28 words
The insoluble pharmaceutical dosage form according to claim 7, wherein said semipermeable membrane is formed from a compound selected from the group consisting of ethylcellulose and cellulose acetate.
Claim 38
Dependent Claim
28 words
The insoluble pharmaceutical dosage form according to claim 7, wherein said active ingredient includes at least one member selected from the group consisting of mydriatics, antibiotics and anti-inflammatories.
Claim 39
Dependent Claim
40 words
The insoluble pharmaceutical dosage form according to claim 7, including by total weight of said dosage form between 1 and 60% of said active ingredient, between 25 and 70% of said polymer, and between 8 and 40% of said glycerides.
Claim 40
Dependent Claim
31 words
The insoluble pharmaceutical dosage form according to claim 7, wherein said dosage form is between approximately 2.5 and 4 mm in length and between approximately 1 and 3 mm in diameter.
Claim 41
Dependent Claim
21 words
The insoluble pharmaceutical dosage form according to claim 7, wherein said first layer of glycerides is also present within the matrix.
Claim 42
Dependent Claim
30 words
The insoluble pharmaceutical dosage form according to claim 7, wherein said semipermeable membrane is formed from a substituted thermoplastic cellulose compound selected from the groups consisting of ethers and esters.
Claim 43
Dependent Claim
14 words
The insoluble pharmaceutical dosage form according to claim 7, wherein said glycerides are triglycerides.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-06-15 | 2001-12-15 | 2002-06-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-06-15 | 2005-12-15 | 2006-06-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-06-15 | 2009-12-15 | 2010-06-16 | $7700.00 | Window Closed / Lapsed |